

# CDSS (Clinical Decision Support Software)

## *Digital Solutions for Improving NCD Care*




**Professor Nikhil Tandon**  
**Department of Endocrinology & Metabolism**  
**All India Institute of Medical Sciences, New Delhi**

# Healthcare Technologies

- Medicines, medical devices, assistive technologies, techniques and procedures developed to solve health problems and improve the quality of life.
- Technology can act as an interface between various stakeholders
- Substantial evidence exists on the diverse role technology can play in several aspects of delivering Healthcare, saving cost and improving quality of care

Source:

<https://www.who.int/europe/news-room/fact-sheets/item/health-technologies>




Source:

<https://globalheartjournal.com/articles/10.5334/gh.1141/>

# NCDs: Continuum of Care

- NCDs (Hypertension & Diabetes) lifelong diseases
- Interventions only at one level will not achieve desired results
- Integration of technology/interventions across levels of the healthcare system to screen, diagnose, track patient outcomes, improve referral linkages, and retain patients in care will ensure continuum of care



# Diabetes

Targets by  
World Health  
Organization (WHO):


For the first time ever, WHO Member States have supported the creation of global targets for diabetes

The five new targets (by 2030):

- 80% of people living with diabetes are diagnosed
  - 80% have good control of glycaemia
  - 80% of people with diagnosed diabetes have good control of blood pressure
  - 60% of people with diabetes of 40 years or older receive statins
  - 100% of people with type 1 diabetes have access to affordable insulin and blood glucose self-monitoring.
-

# National Estimates of the Adult Diabetes Care Continuum in India, 2019-2021

Figure 1. National-Level Diabetes Care Cascade in Analytic Sample by Urban and Rural Residence



# CLINICAL DECISION SUPPORT SYSTEM (CDSS)

- **What is a CDSS?**
  - Computer-based programs that analyze data within EHRs to provide prompts and reminders to assist health care providers in implementing evidence-based clinical guidelines at the point of care.
- **What are key functions of a CDSS in CVD care?**
  - reminding providers to screen for risk factors
  - flagging cases of hypertension or hyperlipidemia
  - providing information on treatment protocols
  - prompting questions on medication adherence
  - providing tailored recommendations for health behavior changes
- **Does a CDSS improve outcomes?**
  - Implementing CDSS is among the Best Practices/Health Care System Interventions
  - Evidence base demonstrating the effectiveness of CDSS is very strong.



# Creating Algorithms

## Glucose Control

**Table 1: Decision Support Table for Glycemia Control**

		Fasting Blood Glucose (mg/dl)		
		<110	110-130	>130
Hba1c (%)	<7	Good control Continue with existing regimen	Fair control (maybe inconsistent HbA1c and FBG) Reinforce lifestyle counseling	Likely poor control (inconsistent HbA1c and FBG) Check post-prandial blood glucose levels Increase* treatment (Take steps to reduce FBG)
	7-8	Likely poor control -Re-check HbA1c -Check post-prandial blood glucose levels -If high, mealtime interventions <sup>§</sup>	Insufficient control Increase* treatment Check post-prandial glucose levels and control	Poor control Greater** increase in treatment Check post-prandial glucose levels and control
	>8	Likely poor control -Re-check HbA1c -Check post-prandial blood glucose levels -If high, mealtime interventions <sup>§</sup>	Poor control Greater** increase in treatment Check post-prandial glucose levels and control	Very poor control Greater** increase in treatment

\***Increase** = 1 of the following possible changes:

- Increase in Metformin dose by 500 mg
- Increase in SU dose by 25% of maximum dose of the sulfonylurea in use<sup>#</sup>
- Increase in pioglitazone by 15 mg (*Rosiglitazone not used widely*)

§ Consider adding one increment of alpha glucosidase inhibitors: 25 mg of acarbose; 25 mg of miglitol; 0.2 mg of voglibose

# 5 mg of glibenclamide; 2 mg of glimepiride; 80 mg of gliclazide; 30 mg of modified release gliclazide

\*\***Greater Increase** = 2 of the following possible changes (2 of the same OR 2 different):

- Increase in Metformin dose by 500 mg
- Increase in SU dose by 25% of maximum dose of the sulfonylurea in use<sup>#</sup>
- 33% increase in maximum pioglitazone

# 5 mg of glibenclamide; 2 mg of glimepiride; 80 mg of gliclazide; 30 mg of modified release gliclazide

# Creating Algorithms

## *Blood Pressure Control*

**Table 2: Decision Support Table for blood pressure control**

Systolic BP					
Diastolic BP	<80	<130	130-140	140-160	>160
		Good control	Fair control -Re-check BP at next visit -Reinforce lifestyle counseling	Likely poor control -Systolic hypertension -Increase treatment (1-2 increment, Consider CCB)	Urgent -Immediate and greater medication (at least 2 increments, consider CCB)
	80-90	Likely poor control  -Re-check BP -Reinforce lifestyle counseling	Insufficient control  Increase treatment (1 increment)	Poor control  Increase treatment (1-2 increments)	Urgent -Immediate and greater medication (at least 2 increments, consider CCB)
	>90	Likely poor control  Increase treatment (1 increment)	Poor control  Increase treatment (1 increment)	Very poor control  Increase treatment (1-2 increments)  -earlier follow-up, in 4 weeks	Very urgent -Immediate and greater medication (at least 2 increments)  -earlier follow-up, every 2 weeks

Concept of “unit” increment similar to that for OHA: e.g. 5 mg amlodipine; 50 mg atenolol



# Creating Algorithms

## *Lipid Management*

**Table 3: Decision Support Table for lipid control**

	LDL cholesterol level (mg/dL)		
With history of previous CVD event	<70	70-100	>100
Without history of previous CVD event	<100	100-130	>130
	Good control	Poor control	Very poor control
	Continue with existing regimen	Increase treatment (1 increment)	Greater increase in treatment (2 increments)


Concept of “unit” increment similar to that for OHA: e.g. 10 mg atorvastatin; 20 mg simvastatin

# Implementing model of care involving technology and existing health system infrastructure


---






# Key Ingredients of the Intervention Package



# Based on evidence accumulated over the past decade in India



HTN: Hypertension, DM: Diabetes Mellitus, DPRS: Depression, ALC: Alcohol, TOB: Tobacco, DSLP: Dyslipidemia



# DSS management plan

	HbA1c	FBG	PPBG
23/Apr/2013	7.5	157.0	146.0
09/Jul/2011	9.5	90.0	125.0
27/May/2011	9.3	134.0	180.0

Likely poor control  
Review SMBG, titrate insulin accordingly  
Weekly phone calls to check SMBG and titrate insulin based on FBG until goal is reached (target:  $< 130$  mg/dL)

**Glycemic prompt**

Yes  
 No

pt has stopped insulin, FBG, PPBG-ok, A1c high, advised diet control

*Reason for rejecting the DSS prompts*

	BP
23/Apr/2013	109.5/82.0
09/Jul/2011	129.0/85.5
27/May/2011	126.0/88.5

Continue with existing regimen

**BP prompt**

Yes  
 No

	TC	LDL	HDL	TG
23/Apr/2013	216.0	143.0	50.0	148.0
09/Jul/2011		107.0		
27/May/2011		124.9		

Increase treatment by 1 increment (Atorvastatin 10 mg, Simvastatin 20 mg, Rosuvastatin 10 mg)  
Follow-up at 3-monthly visit: check lipid profile and LFTs

**LDLc prompt**

Yes  
 No

Diet control

*Physicians review of DSS prompt and agreement as Yes/No*





# CARRS: CDSS & Result

## Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals A Randomized, Controlled Trial

Mohammad K. Ali, MBChB, MSc, MBA; Kavita Singh, MSc; Dimple Kondal, PhD; Raji Devarajan, MSc; Shivani A. Patal, MPH, PhD; Roopa Shivashankar, MD; Vamadevan S. Ajay, MPH, PhD; A.G. Unnikrishnan, MD, DM; V. Usha Menon, PhD; Premalata K. Varthakavi, MD, DNB; Vijay Viswanathan, MD, PhD; Mala Dharmalingam, MD, DM; Ganapati Bantwal, MD, DM; Rakesh Kumar Sahay, MD, DM; Muhammad Qamar Masood, MBBS; Rajesh Khadgawat, MD, DM; Ankush Desai, MD, DM; Bipin Sethi, MD, DM; Dorairaj Prabhakaran, MD, DM; K.M. Venkat Narayan, MD; and Nikhil Tandon, MD, PhD; on behalf of the CARRS Trial Group

Outcomes	Intervention group (N = 575) %	Usual care (N=571) %	Treatment Effect, [95% CI]
Multiple risk factor control HbA1c <7% & either BP <130/80 or LDLc <100 (<70 with history of CVD)	17.7	7.5	2.4 [1.7, 3.3]
HbA1c <7%	20.2	9.6	2.1 [1.5, 2.8]
BP <130/80 mmHg	48.5	38.9	1.2 [1.1, 1.4]
LDLc <100 (<70 with h/o CVD)	51.7	43.3	1.2 [1.1, 1.3]

The screenshot displays a CDSS interface with three main prompts: Glycaemic, BP, and LDLc. Each prompt is associated with a data table and decision options (Yes/No). Red annotations highlight specific areas: a red box around the Glycaemic data table, a red circle around the 'No' option for the Glycaemic prompt with the reason 'pt has stopped insulin, FBG, PPBG-ok, A1c high, advised diet control', and a blue arrow pointing to the 'No' option for the LDLc prompt with the reason 'Physicians review of DS-EHR prompts & agreement as Yes/No'.

	HbA1c	FBG	PPBG
23/Apr/2013	7.5	157.0	146.0
09/Jul/2011	9.5	90.0	125.0
27/May/2011	9.3	134.0	180.0

	BP
23/Apr/2013	109.5/82.0
09/Jul/2011	129.0/85.5
27/May/2011	126.0/88.5


	TC	LDL	HDL	TG
23/Apr/2013	216.0	143.0	50.0	148.0
09/Jul/2011		107.0		
27/May/2011		124.9		




# CARRS:

## Acceptance of CDSS recommendations and impact on clinical parameters


### HbA1c



### sBP




### LDL




# Physicians acceptability of EHR-DSS

Physician Acceptance Rate: EHR-DSS  
Management Prompts



- Acceptance rate across trial sites:
  - **41-93%** for glycaemic prompts
  - **53-98%** for lipids and BP prompts

# Results (cont..)






# Results from another CDSS project mPower Heart Project: Himachal Pradesh

ORIGINAL RESEARCH





Development of a Smartphone-Enabled Hypertension and Diabetes Mellitus Management Package to Facilitate Evidence-Based Care Delivery in Primary Healthcare Facilities in India: The mPower Heart Project


Vamadevan S. Ajay, MPH, DLSHTM, PhD; Devraj Jindal, BDS, MPH; Ambuj Roy, MD, DM; Vidya Venugopal, MS, PhD; Rakshit Sharma, MBA; Abha Pawar, BDS, MPH; Sangya Karna, MD, MRCP, MSc, PhD; Nikhil Tandon, MD, PhD; Dorairaj Prabhakaran, MD, DM, MSc



Results sustained after 18 months



Known	2864	2645	2456	2231	1987	1488	878
New	3152	2952	2614	2609	2417	1897	1124



Known	1045	939	833	728	637	408	236
New	446	410	356	314	281	183	77

**In 2017, adopted by Tripura and Mizoram for state-wide implementation.**

# Integrated Tracking, Referral, and Electronic Decision Support, and Care Coordination (I-TREC)



## AIIMS

Nikhil Tandon, PI

## CCDC

Sailesh Mohan  
D Prabhakaran

## Emory

Shivani Patel  
Mary Beth Weber  
Mohammed K Ali  
KM Venkat Narayan

## NIH/NHLBI

Makeda Williams



Nikhil Tandon



Shivani Patel



Sailesh Mohan



Mary Beth Weber



D. Prabhakaran



Mohammed K Ali



KM Venkat Narayan



Ambuj Roy



Yashdeep Gupta



Hanspria Sharma



Ajay Vamadevan



Devraj Jindal



Priti Gupta



Rakshit Sharma



Prashant Jarhyan



Nikhil SV



Mumtaj Ali

## National Advisory Board

VK Paul-**Chairperson** (NITI Aayog)  
Nikhil Tandon  
DG-ICMR: Balram Bhargava  
WHO India Representative: Roderico H Ofrin  
AS & MD (NHM): Vandana Gurnani  
JS NCD (MOHFW): Vishal Chauhan  
Executive Director (NHSRC): Atul Kotwal  
Principal Secretary Health (Punjab): Hussan Lal

## International Advisory Board


Anushka Patel **Chairperson** (George Institute, Australia)  
Pablo Parel (LSHTM, UK)  
Neil Poulter (Imperial College, London)  
Kamlesh Khunti (University of Leicester, UK)  
Anil Kapur (World Diabetes Foundation)  
Lara Fairall (University of Cape Town, South Africa)







## Non-Communicable Diseases Screening & Management



### Stakeholder Responsibility


- ASHA Community Healthworker.**  
Family Folder, CBAC Forms, Health Cards, Community Mobilizing, Follow-ups
- ANM - Healthworker**  
Screening, referrals, follow-ups. Update health records in tablet and health cards
- MO - Medical Officer**  
Diagnosis and management of HTN and DM. Update health cards. DEO updates portal
- Specialist Doctor - Secondary**  
Screen, diagnose and treat cancers. Update health cards. DEO updates portal for tracking
- Specialist Doctor - Tertiary**  
Screen, diagnose and treat cancers. Update health cards. DEO updates portal for tracking
- All Health Officials**  
Monitor dashboards, view reports, manage program performance, conduct reviews

### PROGRAM ACRONYMS


NCD	Non Communicable Diseases
ASHA	Community Healthworker
ANM	Auxiliary Nurse Midwife
MO	Medical Officer
PHC	Primary Health Center
CBAC	Community Based Assessment Checklist
DEO	Data Entry operator
CHC	Community Health Center
HTN	Hypertension
DM	Diabetes Mellitus

# The evidence-based intervention


## 1. Electronic Case Record Form




## 2. In-built clinical decision support and referral prompts



## 3. Healthcare provider training on lifestyle management of disease



## 4. Modified work flow in healthcare facilities (with task shifting)







Improving care for hypertension and diabetes in india by addition of clinical decision support system and task shifting in the national NCD program: I-TREC model of care

# Need Assessment/Formative work/Experience/Literature

## Identifying gaps in usual care

- Lack of integrated management of chronic conditions, addressing common multiple morbidities
- Inadequate human resource and capacity
- Lack of systematic patient assessment and long-term management of the chronic condition
- Low adherence to long-term care
- Limited patient lifestyle changes/behavioural modification
- Irregular/limited drug supply and lab investigations

## Health facilities readiness for the uptake of digital health intervention

- **Infrastructure**
  - Hardware-tab/computers/printers etc.
  - Electricity and internet connectivity
  - Space
- **Use of digital intervention by healthcare providers**
  - Lack of time
  - Low/limited acceptance among doctors for using technology
  - Limited involvement of the non-physician healthcare workers in using the technology during the patient visits in the health facility

### Objective

To develop a “model of care” entirely incorporated within the current health system, spanning across all levels of healthcare, using the core principles of “task shifting and technology”.

### Steps

- Identification and engagement of key stakeholders
- Development of algorithms for CDSS to provide evidence-based care for diabetes and hypertension in accordance with the level of health facility
- Strengthening the referral pathways for appropriate care of patients at different levels of health care
- Changes in the GoI CPHC-NCD System and Workflow
- Development of CDSS platform and Integration of CDSS with the GoI CPHC-NCD System
- Training of healthcare providers

### Expected Outcomes

- Increase use of CDSS-enabled GoI CPHC-NCD System in the health facilities
- Improved involvement of doctors
- Referral linkages for coordinated care delivery across all levels of the healthcare system hierarchy
- Task-shifting (nurses are involved in the screening of NCDs and initial examination)
- Data availability on important factors

### Key Stakeholders

National Health Mission, Government of India; Department of Health & Family Welfare, Government of Punjab; Health System Staff (District SBS Nagar); Technology and implementation partners (Dell EMC/Tata Trusts); Investigators and study team (I-TREC Team)

# I-TREC CDSS: Algorithms designed for existing infrastructure

## Diabetes:

- Algorithms based on availability of the test results and type of health facility (PHC, CHC, & DH)
  - HbA1C & FBG & PPBG
  - HbA1C & FBG
  - FBG & PPBG
  - Only FBG
  - Only RBG
- OHA & Insulin recommendations and dose titration

## Hypertension:

- Algorithms based on blood pressure readings and type of health facility (PHC, CHC, & DH)
- Anti-hypertensive, Aspirin & Statin recommendation

# Diabetes Management Algorithms: Logic

## Basic principles in the management of T2DM:

- Modify Lifestyle
- Pharmacological Treatment: OHA or Insulin
- No anti-hyperglycemic medicines in use, start with metformin
- If a person is already on OHA, add another OHA (if already given 50% of a particular OHA) or increase the dose of current OHA
- Follow-up prompts: 2 unit/dose or more: after 1 month. 1 unit/ dose - after 3 months.
- In on insulin, SMBG is very important. (with or without SMBG)
- If FBS <70, Review the hypoglycaemic condition and manage accordingly.

## Drug escalation suggestions

- Prompt 1: First increase from two choices [Metformin or SU]
- Prompt 2: If PPBG high but Fasting Normal: Acarbose will come as prompt 3<sup>rd</sup> or 4<sup>th</sup> drug
- If fasting also elevated: Pioglitazone will come as 3<sup>rd</sup> or 4<sup>th</sup> drug prompt
- If already on 3 drugs in maximum dose [open prompts for DPP4/SGLT2]
- After 3 drugs insulin will come as one of the option
- After 4 drugs, suggest only insulin
- Drug Priority: Metformin > SU > Pio > Acarbose > DPP4i > SGLT 2i

# I-TREC CDSS: Algorithms designed for existing infrastructure

PPBS \ FBS	<130	131-160	161-200	>200
<180	Good control	Reinforce Lifestyle	+1 dose	+ 2 dose
181-250	Reinforce Lifestyle	+1 dose	+1 Dose	+ 2 dose
251-300	+1 dose	+1 dose	+2 dose	+ 2 dose
>300	+1 dose	+1 dose	+ 2 dose	Insulin*

FBS	<110	110-130	131-160	161- 200	>200*
	Good control	Reinforce Lifestyle	+1 dose	+ 2 dose	+ 3 dose

PPBS	<140	140-180	181-250	251-300	>300*
	Good control	Reinforce Lifestyle	+ 1 dose	+ 2 dose	+ 3 dose

# Drug prompts based on HbA1c, FBS and PPBS

HbA1c < 7%

PPBS \ FBS	<130	131-160	161-200	>200
<180	Good control	Reinforce Lifestyle	+1 dose	+ 2 dose
180-250	Reinforce Lifestyle	+1 dose	+1 dose	+ 2 dose
251-300	+1 dose	+1 dose	+2 dose	+ 2 dose
>300	+1 dose	+1 dose	+ 2 dose	Insulin*

# Drug prompts based on HbA1c, FBS and PPBS

HbA1c 7-8%

PPBS \ FBS	<130	131-160	161-200	>200
<180	Good control	+1 dose	+1 dose	+ 2 dose
180-250	+1 Dose	+1 dose	+ 2 dose	+ 2 dose
251-300	+1 dose [Check if PPBG has been done in right manner]	+2 dose	+2 dose	+ 2 dose
>300	+1 dose [Check if PPBG has been done in right manner]	+2 dose	+ 2 dose	Insulin*



# Drug prompts based on HbA1c, FBS and PPBS

HbA1c >8%

	FBS	<130	131-160	161-200	>200
PPBS					
<180		Good control [reinforce lifestyle	+1 Dose	+1 dose *	+ 2 dose
180-250		+1 Dose	+2 dose	+ 2 Dose	+ 2 dose
251-300		+1 dose [Check if PPBG has been done in right manner]	+2 dose	+2 dose	+ 2 dose
>300		+1 dose [Check if PPBG has been done in right manner]	+2 dose	+ 2 dose	Insulin**

# Insulin Algorithms

## Insulin Algorithm [Which insulin to start and when]

- Add NPH at bedtime if PPBS-FBS <100
- **Will start Pre-Mixed** (2 times a day), if:
  - HbA1c > 8.5
  - PPBS-FBS > 100
  - NPH > 0.5 unit/kg/day still not control
- If Insulin in use/advised, stop Pioglitazone.

# Insulin Dose Titration


## NPH [bedtime]

- Start by 0.1 units/kg [round off to nearest whole number]
- Continue same OHAs
- Target FPG 100-130
- Titrate by FPG [SMBG every 4<sup>th</sup> day]
- If Fasting plasma glucose 130-149: Increase by 1 unit, 150-169: increase by 2 units; 170-199: increase by 3 units; > 200 increase by 4 units
- Down titrate if BG <80 by 2 units ; 80-99 by 1 unit
- Ask patient to come after 2 weeks for first time than as per need


## Premix

- Start by 0.2 units/kg [Stop SU/PIOZ]
- Divide; 2/3<sup>rd</sup> (M) and 1/3<sup>rd</sup> (E) 30 minutes before meals
- Target FPG 100-130, PPBG 140-180
- Titrate by FPG/PPBG, and pre/post dinner [SMBG every 4<sup>th</sup> day]
- If ABF > 180 **AND** ABF-BBF 40-59: Increase by 1 units; 60-79 by 2 units; 80-99 by 3 units and 100 or more > by 4 units [titration for morning dose]
- If AD > 180 **AND** AD-PREDINNER 40-59: Increase by 1 units; 60-79 by 2 units; 80-99 by 3 units and 100 or more > by 4 units [titration for evening dose]
- If AD and predinner not available: Increase insulin before dinner dose - If FPG 130-149: Increase by 1 unit, 150-169: by 2 units; 170-199: by 3 units; > 200 by 4 units
- Down titrate if after meal is less than or equal to premeal: By 2 units or there is hypoglycemic symptoms.

# Embedding intervention components within GoI physical and IT infrastructure



# CDSS-enabled GoI CPHC-NCD System Architecture



# CDSS enabled Government of India (GoI) CPHC NCD System (No additional hardware/software requirement)

CDSS-enabled GoI CPHC-NCD System Data Flow



Screenshot of the GoI CPHC-NCD (Health facility) System

The screenshot shows the patient summary for hypertension on the ncd-staging.nhp.gov.in portal. The interface includes a navigation bar with icons for Diet, Physical Activity, Weight Control, Avoidance of Alcohol, Tobacco cessation, Drug adherence, and Hypertension complications. The main content area displays patient vitals: Blood Pressure (164 / 102 mmHg), Blood Sugar (120 mg/dl), Heart Rate (80 bpm), and BMI (23.3 (kg/m<sup>2</sup>)). A 'Counselling Done' checkbox is present. The 'History' section shows COPD | Hypertension |. The 'Current Medication' section is empty. The 'Signs & Symptoms' section shows Physical Examination. The 'Recommendation' section includes a note: 'Notes: Beta Blockers are contraindicated.' and a 'Recommended Action: Pharmacological Treatment'. The 'Medication Advice' section shows three options, with Option 2 selected. Below this, a table lists the medication details:


Class	Medicine	Total daily dose (mg)	Strength	Frequency	Duration (in days)	Quantity (in numbers)	Special Instruction
CCB	Amlodipine	5	5	Once a day	30	30	

ASHA: Accredited Social Health Activist; ANM: Auxiliary Nurse Midwife; GoI CPHC-NCD: Government of India Comprehensive Primary Health Care Non-communicable Diseases

# Technology embedded within usual workflow

No additional manpower requirement

Nurse Care Coordinator enters initial assessment and clinical history into CPHC NCD System



- MO receives patient assessment on the NCD portal or as a printout
- MO accepts recommendation or rewrite prescription on NCD Portal or Print-out





# Provider recommendation and Patient Receives Print out

Date: 24<sup>th</sup> Feb 2019

### Recommendation

**Patient Name:** XYZ | 45yrs | Female | Ph: 09793649823 | Patient ID: 1157XXX |  
**History:** Diabetes | Liver Failure  
**Signs & Symptoms:** Polydipsia | Polyuria  
**Pregnant:** No  
**Current Medications:** Metformin 500mg | Amlodipine 5mg | Paracetamol 200mg

#### Past readings

Date	Facility	FBG (mg/dl)	RBG (mg/dl)	PPBG (mg/dl)	HbA1c %	BP (S/D) mmHg	Weight (kg)	BMI
24 <sup>th</sup> Feb 2019	PHC	120	160	140	6	120/80	60	24
10 <sup>th</sup> Feb 2019	PHC	120	150	160	6	110/80	60	24
15 <sup>th</sup> Jan 2019	CHC		160			110/70	60	24
1 <sup>st</sup> Jan 2019	PHC					130/80	60	24
20 <sup>th</sup> Dec 2018	PHC	160		200	7		60	24

#### DIABETES SECTION

Patient Status: Referred to CHC

#### Examination

Readings	FBG (mg/dl)	RBG (mg/dl)	PPBG (mg/dl)	HbA1c %
Nurse	125	220 Venous		
Doctor		<ul style="list-style-type: none"> <li>Capillary</li> <li>Venous</li> </ul>	<ul style="list-style-type: none"> <li>Capillary</li> <li>Venous</li> </ul>	

#### Diagnosis

Recommended Diagnosis:  Diabetes Mellitus (Control : Insufficient)

You can override the above recommended diagnosis by choosing one of the following options

Normal (NAD)  Refer Reason for override

#### Treatment

Notes: Pharmacological Treatment

Recommended Action: Follow the current regimes

Medication Advice: Please choose one of the options as suggested below or create new

Option 1	Option 2
Increase Metformin to max dose 2000.0 mg <b>AND</b> Add Sulfonylurea (Glimepiride 2.0 mg or Glipizide 10.0 mg or Gliclazide 80.0 mg or Modified Release Gliclazide 30.0 mg or Glipizide XL 5.0 mg)	Add Sulfonylurea (Glimepiride 4.0 mg or Glipizide 20.0 mg or Gliclazide 160.0 mg or Modified Release Gliclazide 60.0 mg or Glipizide XL 10.0 mg)
Please specify: (frequency & dosage)	

Custom Plan (Prescribe medicines in this section only if the above suggested options are not available)

Reason for creating custom plan:  Recommended drugs not available  No drug recommended  Other:

### Test

Patient ID:XXXXXX4072

65 Years | Male

History: Diabetes | Hypertension

#### Past Readings

Date	FBS (mg/dl)	RBS (mg/dl)	PPBS (mg/dl)	HbA1c (%)	BP(s/d) (mmHg)	Weight (kgs)	BMI (kg/m2)
04-05-2021	200	-	280	-	160 / 100	-	-
15-04-2021	-	280	-	-	160 / 100	85	26.8

### Diabetes Section

Diagnosis: Diabetes Mellitus

Prescribed on 04-05-2021, PHC

#### Medication Advice

Medicine Name	Strength	Frequency	Duration(in days)	Quantity	Special Instruction
Metformin	500	Twice a day	30	60	After Food

#### Instructions

- Next Visit : Follow up at PHC on 01 Jun 2021
- Referred To : NA

### Hypertension Section

Diagnosis: Hypertension

Prescribed on 04-05-2021, PHC

#### Medication Advice

Medicine Name	Strength	Frequency	Duration(in days)	Quantity	Special Instruction
Enalapril	5	Once a day	30	30	

#### Instructions

- Next Visit : Follow up at PHC on 01 Jun 2021
- Referred To : NA

### Other Complaints



# Uptake of CDSS enabled CPHC NCD System in Health Facilities

## Experience from Punjab: I-TREC Study



	Interview Round 1		Interview Round 2		Interview Round 3	
	Mukandpur (Intervention)	Sujjon (Control)	Mukandpur (Intervention)	Sujjon (Control)	Mukandpur (295)+ DH(503) (Intervention)	Sujjon (Control)
<b>Lifestyle related advice</b>	n=282	n=167	n=377	n=255	n=798	n=250
<b>Lifestyle advice given by doctor, %</b>	100%	98.8%	99.0%	97.3%	99%	61.6%
<b>Diet/daily habits advised by nurse, %</b>	98.9%	68.9%	96.0%	65.5%	91.9%	46.8%

	Interview round 1	Interview round 2	Interview round 3
<b>Portal Usage (Only intervention block)</b>	n= 282	n= 377	n= 798
<b>Computer/tablet used by, %:</b>			
Nurse	99.7%	100%	99.9%
Doctor	96.1%	91.8%	99.5%
<b>Patient received printout, %</b>	<b>87.2%</b>	<b>69.0%</b>	<b>93.4%</b>
<b>Printout given by, %</b>			
<b>*Restricted to those who received a printout</b>			
Nurse	0.4%	0.4%	0.1%
Doctor	99.6%	99.2%	99.1%
Other	0%	0.4%	0.8%



# CDSS Features/Functionalities



**Generate personalized clinical management plan**

**Identify high risk patients and assist in Diagnosis**

**Strengthen Referral Mechanism**

**Follow-up prompts and alert on Contraindication**

**Prompts: optimal generic drug and dosage  
Drug escalation and down-titration**

**Insulin, Hypoglycemia Identification and Management**

**Secondary CVD prevention (Statin & Aspirin prompts)**

**Consider co-morbidities**

Push/Update evolving clinical management guidelines in the backend and Stable platform designed to cover other diseases in future

CDSS enabled GoI CPHC NCD System provides a cafeteria choice of medication thereby not straitjacketing the physician to choose only one drug! It provides generic drug options and includes drugs which are as per IPHS!

All the calculations in the CDSS engine are happening at the back-end. Doctors/healthcare providers do not need to know all the rules. CDSS suggests the preferable drug and dose, along with information about contraindications/notes in a very simple/user-friendly manner.



# Impact

## CDSS enabled Government of India (GoI) CPHC NCD System



- Brings together **task-sharing and technology**-based interventions into a single package
- **Tracks individual patient progress through the various levels of the healthcare system**
- Provides an **electronic clinical decision support system (CDSS)** which assists providers to tailor guideline-based care to individual patient needs
- Strengthen continuum of care- objectively defines **referral thresholds**, strengthens available referral linkages and facilitates referral.
- Trains designated individuals at each level of healthcare in **care coordination** strategies to **improve** continuum of care for people with diabetes and hypertension in India
- Monitors system- and community-level screening and treatment outcomes
- **Standardization of care** across all health facilities (adequate opportunity for patients to explain their illness and complaints to a nurse)
- Reduced workload for medical officers
- Better control of hypertension/diabetes

**Overall Improved Quality of Care**

## Strategies for Stakeholder Engagement and Uptake of New Intervention



Experience From State-Wide Implementation of mHealth Technology for NCD Care in Tripura, India

Devraj Jindal<sup>1</sup>, Ambuj Roy<sup>2</sup>, Vamadevan S. Ajay<sup>3</sup>, Shailesh Kumar Yadav<sup>4</sup>, Dorairaj Prabhakaran<sup>5,6\*</sup>, Nikhil Tandon<sup>7,8\*</sup>

New Delhi and Agartala, India

Annals of Internal Medicine

ORIGINAL RESEARCH

## Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals

A Randomized, Controlled Trial

Mohammed K. Ali, MChB, MSc, MBA; Kavita Singh, MSc; Dimple Kondal, PhD; Raji Devarajan, MSc; Shivani A. Patel, MPH, PhD; Roopa Shivashankar, MD; Vamadevan S. Ajay, MPH, PhD; A.G. Unnikrishnan, MD, DM; V. Usha Menon, PhD; Pramata K. Varthakavi, MD, DM; Vijay Viswanathan, MD, PhD; Mala Dhanalingam, MD, DM; Ganapati Bantwal, MD, DM; Rakesh Kumar Sahay, MD, DM; Muhammad Qamar Maseed, MBBS; Rajesh Khadgawat, MD, DM; Ankur Desai, MD, DM; Bipin Sethi, MD, DM; Dorairaj Prabhakaran, MD, DM; K.M. Venkat Narayan, MD; and Nikhil Tandon, MD, PhD; on behalf of the

ORIGINAL RESEARCH



## Development of a Smartphone-Enabled Hypertension and Diabetes Mellitus Management Package to Facilitate Evidence-Based Care Delivery in Primary Healthcare Facilities in India: The mPower Heart Project

Vamadevan S. Ajay, MPH, DLSHM, PhD; Devraj Jindal, BDS, MPH; Ambuj Roy, MD, DM; Vidya Venugopal, MS, PhD; Rakshit Sharma, MBA; Abha Pawar, BDS, MPH; Sanjay Kinnu, MD, MRCP, MSc, PhD; Nikhil Tandon, MD, PhD; Dorairaj Prabhakaran, MD, DM, MSc

**Background**—The high burden of undetected and undertreated hypertension and diabetes mellitus is a major health challenge worldwide. The mPower Heart Project aimed to develop and test a feasible and scalable intervention for hypertension and diabetes mellitus by task-sharing with the use of a mobile phone-based clinical decision support system at Community Health Centers in Himachal Pradesh, India.

Circulation

ORIGINAL RESEARCH ARTICLE

## Effectiveness of an mHealth-Based Electronic Decision Support System for Integrated Management of Chronic Conditions in Primary Care

The mWellcare Cluster-Randomized Controlled Trial

Editorial, see p 392

Dorairaj Prabhakaran,

RESEARCH

Open Access



# Improving care for hypertension and diabetes in india by addition of clinical decision support system and task shifting in the national NCD program: I-TREC model of care

Devraj Jindal<sup>1\*</sup>, Hanspria Sharma<sup>2</sup>, Yashdeep Gupta<sup>3</sup>, Vamadevan S. Ajay<sup>3</sup>, Ambuj Roy<sup>4</sup>, Rakshit Sharma<sup>2</sup>, Mumtaj Ali<sup>1</sup>, Prashant Jarhyan<sup>1</sup>, Priti Gupta<sup>1</sup>, Nikhil Srinivasapura Venkateshmurthy<sup>1,5</sup>, Mohammed K. Ali<sup>6</sup>, K M Venkat Narayan<sup>7</sup>, Dorairaj Prabhakaran<sup>1,5</sup>, Mary Beth Weber<sup>8</sup>, Sailesh Mohan<sup>1,5</sup>, Shivani A. Patel<sup>8</sup> and Nikhil Tandon<sup>2</sup>



HHS Public Access

Author manuscript

Circulation. Author manuscript; available in PMC 2016 September 01.

Published in final edited form as:

Circulation. 2015 September 1; 132(9): 815–824. doi:10.1161/CIRCULATIONAHA.115.015373.

## A Cluster-Randomized Controlled Trial of a Simplified Multifaceted Management Program for Individuals at High Cardiovascular Risk (SimCard Trial) in Rural Tibet, China and Haryana, India

Maoyi Tian, Ph.D., MSc<sup>1</sup>, Vamadevan S. Ajay, MPH<sup>2,3</sup>, Danzeng Dunzhu, BM<sup>4</sup>, Safraj S. Hameed, MSc<sup>2</sup>, Xian Li, M.D., MSc<sup>1</sup>, Zhong Liu, MEd<sup>4</sup>, Cong Li, BM<sup>1,2</sup>, Hao Chen, M.D.<sup>5</sup>



Global Health Action

ISSN: 1654-9716 (Print) 1654-9880 (Online) Journal homepage: <https://www.tandfonline.com/loi/gha20>

Development of mWellcare: an mHealth intervention for integrated management of hypertension and diabetes in low-resource settings



NIH Public Access

Author Manuscript

Diabetes Res Clin Pract. Author manuscript; available in PMC 2013 November 01.

Published in final edited form as:

Diabetes Res Clin Pract. 2012 November ; 98(2): 285–294. doi:10.1016/j.diabres.2012.09.023.

## Improving diabetes care: Multi-component Cardiovascular Disease Risk Reduction Strategies for People with Diabetes in South Asia - The CARRS Multi-center Translation Trial

CARRS Trial Writing Group, Seema Shah, MD<sup>1</sup>

Srinivasapura Venkateshmurthy et al. Trials (2016) 19:429  
<https://doi.org/10.1186/s12913-016-2613-2>

Trials

STUDY PROTOCOL

Open Access



m-Power Heart Project - a nurse care coordinator led, mHealth enabled intervention to improve the management of hypertension in India: study protocol for a cluster randomized trial



# 1: CDSS + Task-sharing

**OPERATIONAL GUIDELINES**  
**NATIONAL PROGRAMME FOR PREVENTION AND CONTROL OF**  
**NON-COMMUNICABLE DISEASES**  
**(2023-2030)**




Figure 6: Clinical Decision Support System (CDSS) Integrated Patient Pathway

It is a robust system with adaptable algorithms which can be updated time-to-time. Additional, diseases or conditions under NP-NCD programme can be included on the platform. Details on the National NCD Portal architecture is placed as **Annexure 8**.

Primary Care

State-wide  
 Tripura  
 Mizoram

National Level

International  
 Maldives

Ever Heart  
 ct

, DM

HTN

ellcare Trial

, DM, DPRS,  
 , TOB

mPower Heart  
 Platform

•HTN, DM, DSLP,  
 COPD, Cancer

I-TREC CDSS  
 platform

• HTN, DM

mPEN mPower  
 Platform

•HTN, DM, COPD,  
 Asthma, Cancer,  
 ALC, TOB

## Future Plans

- Scaling up by formal integration with GoI CPHC NCD system
- Integration with e-Hospital NIC
- Integration with Ayushman Bharat Digital Mission

2010/ 2019

2012-2013

2012- 2020

2017 Onwards

2017 onwards

2018-2019

**REVISED OPERATIONAL  
GUIDELINES NATIONAL  
PROGRAMME FOR PREVENTION  
& CONTROL OF CANCER,  
DIABETES, CARDIOVASCULAR  
DISEASES & STROKE**

**DRAFT**

**MINISTRY OF HEALTH AND FAMILY  
WELFARE**


**Annexure 7: Clinical Decision Support Software enabled  
CPHC NCD system: Good practices**

CDSS is a computer-based program/system embedded within the CPHC NCD application that analyzes patient data in real-time to provide prompts and reminders to assist healthcare providers in implementing evidence-based clinical guidelines during the clinic visit. Research has shown that the CDSS aided by task-shifting can facilitate guideline-based clinical management of patients and together improve patient outcomes across diverse clinic settings. The CDSS algorithms provide the clinician with a “real time” advisory regarding medication titration based on patient history and current clinical examination as inputted into the eCRF/CPHC NCD System.

States can opt for the CDSS enabled CPHC NCD system. Using the CDSS-enabled CPHC NCD System does not impair any other current data and functionalities of the CPHC NCD System. Also, it does not require any additional manpower or resources. More details about the CDSS enabled CPHC NCD system are given in ***Annexure # 7 (page # 109 of 126).***

# Contributors

*We acknowledge the contributions of various government, academic, research, and technology institutions in supporting our endeavors to work towards improving healthcare.*



*This journey would not have been successful without the enthusiasm and support of several Primary Care Doctors, Nurses, Community Health Workers and Policy Makers. Finally, to the patients without whom we don't exist we express our deepest gratitude*